Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life

The treatment of hepatitis C virus has changed dramatically with the rapid advent of numerous new antiviral agents, including direct-acting antivirals and agents with non-viral targets (cyclophilin inhibitors, interferon-lambda, vaccine therapy). Given the better safety profile and high antiviral po...

Descripción completa

Detalles Bibliográficos
Autores principales: Pol, Stanislas, Corouge, Marion, Vallet-Pichard, Anaïs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786064/
https://www.ncbi.nlm.nih.gov/pubmed/27019602
http://dx.doi.org/10.2147/HMER.S62014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786064/
https://www.ncbi.nlm.nih.gov/pubmed/27019602
http://dx.doi.org/10.2147/HMER.S62014

Ejemplares similares